#ASH23RF - Twitter Hashtag

almost 3 years ago

Learned today from @Mohty_EBMT that Perseus was a demigod (son of Zeus) who killed Medusa. Medusa was treacherous but finally was defeated. Medusa is what myeloma is becoming! Bye! #ASH23RF #mmsm

1

19

5

1

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

History in the making at LBA. A phase 3 trial of Daratumumab-VRD vs RVD for TE MM. Superb results with PFS that approximates 85% at4 years #ASH23RF #mmsm

Rfonsi1's tweet photo. History in the making at LBA. A phase 3 trial of Daratumumab-VRD vs RVD for TE MM. Superb results with PFS that approximates 85% at4 years
#ASH23RF #mmsm https://t.co/REONWeOeVU

3

106

33

17

16K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

The ASH meeting is my favorite celebration of the year. Anyone else? #ASH23RF #mmsm

2

25

0

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

MonumenTAL-2 Tal+Pom by @MileHighMyeloma Neutropenia common. No reduction CD19 B cells. Infections seem more neutropenia linked? Expected tox common (70-80%). While g1/2 imp to monitor - reported no d/c. Good activity. #ASH23RF #mmsm

Rfonsi1's tweet photo. MonumenTAL-2 Tal+Pom by @MileHighMyeloma Neutropenia common. No reduction CD19 B cells. Infections seem more neutropenia linked? Expected tox common (70-80%). While g1/2 imp to monitor - reported no d/c. Good activity.
#ASH23RF #mmsm https://t.co/NwvsDRZHvc

0

13

8

3

2K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Paul Richardson eloquently presenting mezigdomide (henceforth mezi) plus daratumumab or Elo. RRMM n=59 w dara. Only 9% prior dara. Myelosuppression ORR 78% There might be a signal. #ASH23RF #mmsm

Rfonsi1's tweet photo. Paul Richardson eloquently presenting mezigdomide (henceforth mezi) plus daratumumab or Elo. RRMM n=59 w dara. Only 9% prior dara. Myelosuppression ORR 78%

There might be a signal.

#ASH23RF #mmsm https://t.co/9ndy2CYs9u

0

3

0

3

735

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

HPN217 BCMA targeting without Fc domain. Dose escalation. N=97med pLOT 6 CRS 30% mostly g1/2. Transaminitis. Neuro 22% mostly low grade. Infections ~60%. One death subdural. ORR at 12mg 63%. DOR 20.5 mos #ASH23RF #mmsm

Rfonsi1's tweet photo. HPN217 BCMA targeting without Fc domain. Dose escalation. N=97med pLOT 6 CRS 30% mostly g1/2. Transaminitis. Neuro 22% mostly low grade. Infections ~60%. One death subdural. ORR at 12mg 63%. DOR 20.5 mos
#ASH23RF #mmsm https://t.co/7RhEnB9UOq

0

4

1

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Sonrotoclax for t(11;14) RRMM +dex. Ph1b/2. More potent? Low numbers but very interesting. Very safe and active. Time to defeat the t(11;14)!! #ASH23RF #mmsm @SusanBal9 @agarwalonc @bhemato

Rfonsi1's tweet photo. Sonrotoclax for t(11;14) RRMM +dex. Ph1b/2. More potent? Low numbers but very interesting. Very safe and active. Time to defeat the t(11;14)!!
#ASH23RF #mmsm @SusanBal9 @agarwalonc @bhemato https://t.co/8R4Sf4iyPH

4

33

8

3

7K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

MonumrnTAL-1 dose reduction of talquetamab - did not appear to affect efficacy. Most toxicities improved but not weight loss. Perhaps less T cell exhaustion. As has been the case for many drugs we just need to find the right dose. #ASH23RF #mmsm

1

35

10

4

7K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

A randomized Ph 3 study of Pd vs Pcd in RR MM by the Asian Myeloma Network by Prof @chngwj - PFS. n=125. 3 prior LOT. 10.9 vs 5.9 mo. Orr 61 vs 38%. DOR 12 vs 5. #ASH23RF #mmsm

0

12

4

1

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Myeloma XII trial looking at ixazomib consolidation post salvage SCT (ixa needs a shot of energy!). I had stopped using ixa (due to Rosginol and Tourmaline data) but this seems intriguing. Perhaps simply “more of a good drug” #ASH23RF #mmsm

Rfonsi1's tweet photo. Myeloma XII trial looking at ixazomib consolidation post salvage SCT (ixa needs a shot of energy!). I had stopped using ixa (due to Rosginol and Tourmaline data) but this seems intriguing. Perhaps simply “more of a good drug”
#ASH23RF #mmsm https://t.co/yfEf4jytml

0

3

2

1

927

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Long term FU (8 yrs). Salvage SCT vs Len dex n=282. No survival difference in a population with low prior Len use. Given Len is globally generic there are very few cases where rescue SCT should be used if len naive. #ASH23RF #mmsm

Rfonsi1's tweet photo. Long term FU (8 yrs). Salvage SCT vs Len dex n=282. No survival difference in a population with low prior Len use. Given Len is globally generic there are very few cases where rescue SCT should be used if len naive.
#ASH23RF #mmsm https://t.co/zNtT44crnB

3

28

10

4

14K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

#ASH23RF #mmsm

Ben Derman @bdermanmd

almost 3 years ago

IsKia the way to go? MRD as the primary endpoint: 1️⃣ precludes reg approval for isakrd - maybe IMROZ will get Isa into frontline? 2️⃣ sets the stage for understanding how change in MRD corresponds w/change in PFS/OS 3️⃣ will show how outcomes differ for 10^-5 and 10^-6 neg #ASH23

bdermanmd's tweet photo. IsKia the way to go?
MRD as the primary endpoint:
1️⃣ precludes reg approval for isakrd - maybe IMROZ will get Isa into frontline?
2️⃣ sets the stage for understanding how change in MRD corresponds w/change in PFS/OS
3️⃣ will show how outcomes differ for 10^-5 and 10^-6 neg #ASH23 https://t.co/htn9EZ7W1T

3

34

13

9

6K

0

3

0

990

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

We are close to transitioning from “preponderance of evidence” to “beyond any reasonable doubt” in asserting Daratumumab-Rd is a superior choice over VRD for FL TIE MM #VRDisdead #ASH23RF #mmsm

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

almost 3 years ago

#ASH23 #ASHkudos to Dr. Hansen for tackling third rail of #MMsm - D-Rd or VRd-lite for ASCT-ineligible? After IPTW matching, D-Rd clearly outperformed VRd re: TTNT. I think biggest driver of D-Rd vs VRd is where the oncologist trained, not patient factors, so this seems real!

RahulBanerjeeMD's tweet photo. #ASH23 #ASHkudos to Dr. Hansen for tackling third rail of #MMsm - D-Rd or VRd-lite for ASCT-ineligible?

After IPTW matching, D-Rd clearly outperformed VRd re: TTNT.

I think biggest driver of D-Rd vs VRd is where the oncologist trained, not patient factors, so this seems real! https://t.co/lZ2pXYxR7b

4

36

10

3

27K

3

26

5

5K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Dr. @HiraSMian provides a robust and sobering answer on the limitations of therapy in advanced MM. We don’t yet have enough solutions. Who would have thought that a RWE session would pack a room! And special thanks to @JanssenUSOncMed - #JJIM #ASH23RF #mmsm

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

almost 3 years ago

#ASH23 great work by @HiraSMian @Rfonsi1 et al about “quad-exposed” #MMsm including BCMA. >300 pts analyzed, TTNT only 6.4 months. (Similar to MAMMOTH PFS only 3.4 months with triple-exposed). Good benchmark for future studies - we need to do better!

RahulBanerjeeMD's tweet photo. #ASH23 great work by @HiraSMian @Rfonsi1 et al about “quad-exposed” #MMsm including BCMA.

>300 pts analyzed, TTNT only 6.4 months. (Similar to MAMMOTH PFS only 3.4 months with triple-exposed).

Good benchmark for future studies - we need to do better! https://t.co/mxVT3bEtVb

3

22

9

2

7K

1

18

3

2

5K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

@NBahlis presenting update on daratumumab+ven+dex in RRMM. Ph 1/2 1ry endpt PFS. ORR 96.4% MRD 40 -5/25 -6. Median PFS 46 mo. OS at 5 years at 5 years >75% in MRD- Only one infectious death. #ASH23RF #mmsm

0

16

5

0

1K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Higher baseline ALC = higher risk of ICANS. Higher fibrinogen and ferritin lead to shorter OS #ASH23RF #mmsm

1

28

7

3

3K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

@Mohty_EBMT @MMTrials @TheIACH @COMyCongress #ASH23RF #mmsm

0

2

0

431

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

RWE teclistamab in MM n=106, 53% prior BCMA. ORR 66% CRv29%. Lower in EMD. Responses in those with prior exposure (ORR 80%). Safety similar. Cytopenias common but mostly g1/2. Infections common. Viral. #ASH23RF #mmsm

2

31

10

3

4K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Is there any further doubt that VRD is dead? #ASH23RF #mmsm

8

27

6

3

22K

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

almost 3 years ago

Is someone working on T- cell @Gatorade? Apparently these cells get exhausted! #ASH23RF #mmsm

3

18

3

0

8K

Top Tweets for #ASH23RF

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users